相关实验视频

Updated: Jun 22, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

通过准MIOS来开发一个Tanshinone IIA记忆剂,以调节mTORC1和质母细胞瘤中的自

Sonia Shinhmar¹, Judith Schaf¹, Katie Lloyd Jones¹

¹Centre for Biomedical Sciences, School of Biological Sciences, Royal Holloway University of London, Egham TW20 0EX, UK.

International journal of molecular sciences

|June 27, 2024

概括

坦西诺IIA (T2A) 通过抑制mTORC1并通过塞斯特林2 (SESN) 和MIOS诱导自,对质母细胞瘤治疗具有前景. 一种新型化合物Mi3模仿T2A.

科学领域:

生物化学生物化学
分子生物学分子生物学
癌症研究癌症研究

背景情况:

多形质母细胞瘤 (GBM) 是一种具有攻击性的脑瘤.
坦辛IIA (T2A) 显示出对GBM的治疗潜力.
T2A抑制了mTORC1并诱导了自,可能是通过斯特林2 (SESN).

研究的目的:

研究T2A在调节SESN,MIOS,mTORC1和自的机制.
确定模仿T2A对GBM细胞影响的新型化合物.

主要方法:

使用了*Dictyostelium discoideum*和人类的GBM细胞系.
进行基因切除 (sesn-,mios-) 和化合物查.
在药物发现中使用计算分析.

主要成果:

在*D. discoideum*中诱导T2A自和抑制mTORC1,依赖于SESN和MIOS.
计算查发现MIOS抑制剂3 (Mi3) 是一个潜在的T2A模仿剂.
Mi3 降低了 GBM 细胞增殖,抑制了 mTORC1,并诱导了自,其特异性在 *D. discoideum* 中得到证实.

结论:

通过SESN和MIOS,T2A通过自和mTORC1进行调节.
在GBM治疗中,Mi3是潜在的T2A模仿剂.
准MIOS为质母细胞瘤提供了一个新的治疗策略.

关键词:

迪克托斯利乌姆迪斯科伊迪乌姆在GATOR2中,我们可以使用GATOR2.我们的MIOS是MIOS.自自是自的过程.癌症癌症癌症癌症癌症发现药物的发现.质母细胞瘤 (glioblastoma) 是一种在 mTORC1 的情况下,mTORC1 是塞斯特里尼·塞斯特里尼·塞斯特里尼坦西诺 IIA 类型的

更多相关视频

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells

siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells

Published on: October 28, 2019

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...